Shriram Pistons & Rings Ltd (SHRIPISTON) Q2FY26 Concall Summary - Sep-2025 Qtr
Performance Overview
- The company demonstrated resilience in Q2 and H1 FY26, achieving a consolidated total income growth of 14.9% year-on-year and consolidated EBITDA growth of 14.2% year-on-year despite challenging auto industry conditions due to geopolitical situations and muted domestic market growth.
- Consolidated total income for Q2 FY26 grew by 15% year-on-year, maintaining a consolidated EBITDA margin of 22.4% and a consolidated PAT margin of 13.6%.
- The domestic automotive industry showed mixed performance in Q2, with passenger vehicles declining by 1% while 2-wheelers registered a healthy 7% growth, though GST reforms implemented on September 22, 2025, impacted sales mix in August and September.
- Post GST reduction (GST 2.0), demand improved during the festive season and continued into October, with passenger vehicles, 2-wheelers, 3-wheelers, and commercial vehicle segments all recording double-digit sales growth, rekindling hopes for strong Q3 volumes.
- The company continued to outperform the industry, driven by diverse market and product segments, healthy performance from subsidiaries (including EV and high-precision injection moulded components), new business wins, process efficiency, and cost optimization.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.